Quantification of transcriptome changes to investigate the role of glucocorticoid receptor-RNA binding during dexamethasone treatment

BMC Res Notes. 2023 Aug 22;16(1):181. doi: 10.1186/s13104-023-06446-4.

Abstract

Objectives: The glucocorticoid receptor (GR) is a well-studied, ligand-activated transcription factor and a common target of anti-inflammatory treatments. Recently, several studies have drawn attention the effects of binding of GR to RNA rather than DNA and the potential implications of this activity for GR function. The objective of our study was to further characterize the relationship between GR function and RNA binding by measuring changes in the glucocorticoid-driven transcriptome in the presence of a GR mutant that exhibited reduced RNA affinity.

Data description: GR was activated in three cell lines containing GR constructs (GR-HaloTag). One of the cell lines contained a wild-type GR-HaloTag. Another contained GR-HaloTag with a mutation that reduced RNA affinity and slightly reduced DNA affinity. The third cell line contained GR-HaloTag with a mutation that only slightly reduced DNA affinity. All three cell lines were treated with dexamethasone, a GR agonist. RNA-seq samples were collected every hour for 3 h. Moreover, transcriptome quantification was accomplished via labeling of RNAs transcribed in the final hour of dexamethasone treatment using 4-thiouridine. These labeled RNAs were then purified and sequenced. This data set is the first of its kind for GR and contains valuable insights into the function of RNA binding by GR.

Keywords: 4-thiouridine; Glucocorticoid receptor; NR3C1; RNA binding; RNA sequencing; Transcription factor; Transcriptomics.

MeSH terms

  • Dexamethasone / pharmacology
  • Glucocorticoids / pharmacology
  • RNA
  • Receptors, Glucocorticoid* / genetics
  • Transcriptome*

Substances

  • Receptors, Glucocorticoid
  • Glucocorticoids
  • RNA
  • Dexamethasone